AstraZeneca (AZN)
92.77
0.00 (0.00%)
Upcoming Events
Latest Headlines
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
September 4, 2026 7:03 PM - BizWire
FDA approves AstraZeneca breast cancer drug Etcamah via accelerated path
September 4, 2026 3:41 PM - StreetInsider
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
September 4, 2026 6:06 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 12:20 PM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 12:09 PM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 7:36 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 7:27 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 7:19 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 7:10 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Sep 01
September 1, 2026 7:04 AM - SEC Filing
AstraZeneca closes $600M deal for lung cancer drug Zegfrovy
September 1, 2026 7:00 AM - StreetInsider
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
September 1, 2026 7:00 AM - BizWire
EU approves Enhertu combo for first-line HER2-positive breast cancer
September 1, 2026 6:09 AM - StreetInsider
AstraZeneca acquires worldwide rights to lung cancer drug Zegfrovy
September 1, 2026 6:09 AM - StreetInsider
AstraZeneca's Tagrisso combo shows Phase III benefit in lung cancer
September 1, 2026 6:08 AM - StreetInsider
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
September 1, 2026 2:30 AM - BizWire
Alnylam stock drops on rival heart trial: Why analysts see core business safe
August 28, 2026 8:25 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Aug 27
August 27, 2026 7:05 AM - SEC Filing
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
August 27, 2026 7:00 AM - BizWire
AstraZeneca's Tezspire meets endpoints in esophagitis trial
August 27, 2026 6:04 AM - StreetInsider
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026 9:20 AM - StreetInsider
Daiichi Sankyo and AstraZeneca start phase 3 urothelial cancer trial
August 26, 2026 7:00 AM - StreetInsider
TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
August 26, 2026 7:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Aug 25
August 25, 2026 7:04 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Aug 19
August 19, 2026 9:44 AM - SEC Filing
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
August 19, 2026 8:56 AM - StreetInsider
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
August 17, 2026 7:30 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Aug 17
August 17, 2026 7:15 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Aug 17
August 17, 2026 7:09 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Aug 17
August 17, 2026 7:04 AM - SEC Filing
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer
August 17, 2026 7:00 AM - BizWire
AstraZeneca halts Phase III lung cancer trial after data review
August 17, 2026 6:02 AM - StreetInsider
AstraZeneca's Tagrisso and Orpathys combo meets Phase III goals
August 17, 2026 6:02 AM - StreetInsider
Enhertu meets main goal in phase 3 lung cancer trial
August 17, 2026 2:30 AM - StreetInsider
Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Ca
August 17, 2026 2:30 AM - BizWire
Morgan Stanley analysts visit National Resilience facility in Ohio, clients include LLY and AZN
August 12, 2026 12:04 PM - StreetInsider
Form 4 ASTRAZENECA PLC For: Aug 06 Filed by: Sharma Mani
August 7, 2026 11:41 AM - SEC Filing
AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
August 5, 2026 8:31 AM - StreetInsider
Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
August 5, 2026 8:14 AM - StreetInsider
'No Discussions' Over Astrazeneca-Bristol Myers Deal, Senior Source Says - Reuters
August 5, 2026 8:07 AM - StreetInsider
SOPHiA Genetics and AstraZeneca team up on two cancer diagnostics
August 4, 2026 6:15 AM - StreetInsider
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
August 4, 2026 6:15 AM - PR NewsWire
UBS Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
August 4, 2026 5:33 AM - StreetInsider
Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?
August 3, 2026 11:24 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Aug 03
August 3, 2026 10:45 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Aug 03
August 3, 2026 10:29 AM - SEC Filing
AstraZeneca reviews potential Bristol Myers deal, Barclays comments
August 3, 2026 8:17 AM - StreetInsider
AstraZeneca (AZN) call put ratio 1.7 calls to 1 put into share price lower before the bell
August 3, 2026 5:50 AM - StreetInsider
Bernstein says risk-reward is positively skewed for this pharma stock
August 1, 2026 10:00 PM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Jul 31
July 31, 2026 6:54 AM - SEC Filing
EU approves AstraZeneca and Daiichi Sankyo's Datroway for breast cancer
July 31, 2026 4:06 AM - StreetInsider
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
July 31, 2026 2:30 AM - BizWire
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP178 at Citi
July 28, 2026 5:06 AM - StreetInsider
AstraZeneca says adjusting drug pricing over Trump policies
July 27, 2026 8:59 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Jun 30
July 27, 2026 7:52 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jul 27
July 27, 2026 7:08 AM - SEC Filing
AstraZeneca drug shows survival benefit in gastric cancer trial
July 27, 2026 7:06 AM - StreetInsider
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
July 27, 2026 7:05 AM - BizWire
AstraZeneca results: H1 and Q2 2026
July 27, 2026 7:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Jul 27
July 27, 2026 6:57 AM - SEC Filing
AstraZeneca (AZN) Tops Q2 EPS by 14c
July 27, 2026 6:14 AM - StreetInsider
AstraZeneca's Ultomiris misses primary endpoint in adult HSCT-TMA trial
July 27, 2026 6:06 AM - StreetInsider
AstraZeneca drug shows survival benefit in gastric cancer trial
July 27, 2026 6:06 AM - StreetInsider
AstraZeneca (AZN) Q2 earnings preview
July 26, 2026 8:00 PM - StreetInsider
Enhertu combination gets EU approval recommendation for breast cancer
July 24, 2026 7:39 AM - StreetInsider
EU panel backs Enhertu plus pertuzumab for HER2+ breast cancer
July 24, 2026 7:00 AM - StreetInsider
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
July 24, 2026 7:00 AM - BizWire
AstraZeneca's Trixeo receives EU recommendation for asthma treatment
July 24, 2026 6:50 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Jul 23
July 23, 2026 6:05 AM - SEC Filing
AstraZeneca (AZN) PT Lowered to $205 at Morgan Stanley
July 16, 2026 6:46 AM - StreetInsider
AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP153 at Morgan Stanley
July 16, 2026 4:30 AM - StreetInsider
Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright
July 14, 2026 6:54 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Jul 14
July 14, 2026 6:37 AM - SEC Filing
AstraZeneca licenses sunvozertinib from Dizal for $600M upfront
July 14, 2026 5:52 AM - StreetInsider
AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
July 13, 2026 7:06 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright
July 13, 2026 6:38 AM - StreetInsider
HSBC Downgrades AstraZeneca (AZN:LN) (AZN) to Hold
July 13, 2026 2:24 AM - StreetInsider
Bernstein keeps telling clients to buy this pharma stock
July 11, 2026 4:00 AM - StreetInsider
Buy the pullback in this major pharma stock: Bernstein
July 10, 2026 9:00 AM - StreetInsider
AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP175 at Citi
July 10, 2026 5:05 AM - StreetInsider
AstraZeneca (AZN) call put ratio 1.9 calls to 1 put with a focus on July 180 and 190 calls
July 9, 2026 2:39 PM - StreetInsider
AstraZeneca's Wainua fails primary endpoint in heart trial
July 9, 2026 6:18 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Jul 09
July 9, 2026 6:17 AM - SEC Filing
Form 4 ASTRAZENECA PLC For: Jul 06 Filed by: Sharma Mani
July 8, 2026 4:30 PM - SEC Filing
AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP165 at HSBC
July 6, 2026 1:32 AM - StreetInsider
Abbisko and AstraZeneca to trial oral PD-L1 drug with Tagrisso
July 2, 2026 3:20 AM - StreetInsider
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NS
July 1, 2026 9:00 PM - PR NewsWire
Form 6-K ASTRAZENECA PLC For: Jul 01
July 1, 2026 10:11 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jul 01
July 1, 2026 10:07 AM - SEC Filing
Barclays Reiterates Overweight Rating on AstraZeneca (AZN:LN) (AZN)
June 30, 2026 4:24 AM - StreetInsider
Form 11-K ASTRAZENECA PLC For: Dec 31
June 29, 2026 2:31 PM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jun 29
June 29, 2026 6:45 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jun 29
June 29, 2026 6:06 AM - SEC Filing
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
June 29, 2026 2:30 AM - BizWire
AstraZeneca's Datroway recommended for EU approval in breast cancer
June 26, 2026 7:05 AM - StreetInsider
EU panel backs Datroway for metastatic breast cancer patients
June 26, 2026 7:01 AM - StreetInsider
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026 7:00 AM - BizWire
AstraZeneca and YMCA of the USA form five-year cancer care deal
June 24, 2026 9:01 AM - StreetInsider
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
June 24, 2026 9:00 AM - BizWire
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
June 22, 2026 8:30 AM - StreetInsider
Form 4 ASTRAZENECA PLC For: Jun 08 Filed by: Sharma Mani
June 16, 2026 4:05 PM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jun 15
June 15, 2026 6:52 AM - SEC Filing
AstraZeneca unit receives FDA priority review for rare kidney disease treatment
June 15, 2026 3:00 AM - StreetInsider
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 12, 2026 6:44 PM - BizWire
AstraZeneca receives FDA approval for Truqap prostate cancer treatment
June 12, 2026 2:03 PM - StreetInsider
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
June 9, 2026 2:54 AM - StreetInsider
AstraZeneca's Ultomiris shows 46.6% reduction in kidney protein levels
June 8, 2026 3:02 AM - StreetInsider
Full Article List
